Home > Riviste > Otorinolaringologia > Fascicoli precedenti > Otorinolaringologia 2018 March;68(1) > Otorinolaringologia 2018 March;68(1):2-5

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

OTORINOLARINGOLOGIA

Rivista di Otorinolaringologia, Chirurgia Maxillo-Facciale,
Chirurgia Plastica Ricostruttiva, Otoneurochirurgia


Indexed/Abstracted in: EMBASE, Scopus


eTOC

 

ORIGINAL ARTICLE  FREEfree


Otorinolaringologia 2018 March;68(1):2-5

DOI: 10.23736/S0392-6621.17.02147-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Short-term result of mannitol administration on hearing loss improvement in Menière’s disease and in sensorineural low-frequency fluctuating hearing loss without vertigo

Andrea ALBERA, Roberto ALBERA , Andrea CANALE, Federico CARANZANO, Carmine F. GERVASIO

Department of Surgical Sciences, University of Turin, Turin, Italy


PDF  


In 1995 Menière’s disease has been classified by an international guideline, on the basis of auditory and vestibular symptoms, in four different forms: certain, definite, probable and possible. According to this guideline fluctuating low frequency hearing loss was considered as possible Menière’s disease. Since the administration of osmotic diuretic, such as mannitol, has been proposed in diagnosis and therapy it is the aim of this paper to evaluate if there are some differences is the hearing threshold modification after mannitol administration in two groups of patients affected by possible and definite Menière’s disease. The study was carried out on 137 patients affected by definite (39%) and possible (61%) Menière’s disease, according to 1995 guidelines, and submitted to 18% (intravenous) IV mannitol therapy. After therapy we have found in both groups a significant improvement of hearing threshold in about 30% of cases. Improvement was not related with sex, age and age of appearance of symptomatology while it was related with the duration of the disease that was significantly shorter in subjects who showed a significant hearing improvement. In conclusion IV mannitol administration is a reliable therapy in improving acute hearing loss in possible and definite Menière’s disease.


KEY WORDS: Hearing loss - Menière disease - Mannitol

inizio pagina

Publication History

Issue published online: January 18, 2018
Manuscript accepted: December 5, 2017
Manuscript received: December 3, 2017

Per citare questo articolo

Albera A, Albera R, Canale A, Caranzano F, Gervasio CF. Short-term result of mannitol administration on hearing loss improvement in Menière’s disease and in sensorineural low-frequency fluctuating hearing loss without vertigo. Otorinolaringol 2018;68:2-5. DOI: 10.23736/S0392-6621.17.02147-6

Corresponding author e-mail

roberto.albera@unito.it